Thermo Fisher Scientific (TMO) Income from Continuing Operations (2009 - 2026)

Thermo Fisher Scientific has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 1664000000.0 for Q1 2026.

• Quarterly Income from Continuing Operations rose 9.11% year-over-year to 1664000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6900000000.0 (up 4.61% YoY) and the FY2025 annual result came in at 6761000000.0, up 5.97% from the prior year.
• Income from Continuing Operations slipped to 1664000000.0 in Q1 2026, from 2000000000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 2239000000.0 in Q2 2022 and troughed at 1308000000.0 in Q1 2024.
• A 5-year average of 1644117647.06 and a median of 1619000000.0 in 2025 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 41.18% — and 2024, when it grew 18.8%.
• Tracing TMO's Income from Continuing Operations over 5 years: stood at 1604000000.0 in 2022, then climbed by 0.19% to 1607000000.0 in 2023, then climbed by 11.45% to 1791000000.0 in 2024, then increased by 11.67% to 2000000000.0 in 2025, then slipped by 16.8% to 1664000000.0 in 2026.
• Business Quant data shows TMO's Income from Continuing Operations at 1664000000.0 in Q1 2026, 2000000000.0 in Q4 2025, and 1619000000.0 in Q3 2025.